Orbis Allan Gray Ltd Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• Orbis Allan Gray Ltd significantly increased its stake in Genmab A/S by 102.8%, holding 5,710,741 shares valued at approximately $111.8 million.
• Wall Street analysts have increased target prices for Genmab A/S, with HC Wainwright raising it from $35.00 to $36.00, while Zacks Research lowered its rating from "strong-buy" to "hold."
• Genmab A/S reported quarterly earnings of $0.54 EPS, exceeding the consensus estimate by $0.15, although its revenue was lower than expected at $925 million.

Orbis Allan Gray Ltd increased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 102.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,710,741 shares of the company's stock after purchasing an additional 2,895,179 shares during the quarter. Orbis Allan Gray Ltd owned approximately 0.89% of Genmab A/S worth $111,816,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Headlands Technologies LLC increased its position in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after purchasing an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares in the last quarter. Barclays PLC grew its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Genmab A/S in the 4th quarter valued at $60,000. Finally, Brooklyn Investment Group grew its holdings in Genmab A/S by 729.3% in the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock valued at $83,000 after buying an additional 3,734 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GMAB shares. HC Wainwright upped their target price on Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, August 15th. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Truist Financial upped their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded up $1.02 during trading hours on Tuesday, hitting $25.89. The company's stock had a trading volume of 2,116,986 shares, compared to its average volume of 1,440,319. The firm has a fifty day moving average of $22.31 and a 200-day moving average of $21.31. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $27.91. The stock has a market cap of $16.61 billion, a price-to-earnings ratio of 13.01, a P/E/G ratio of 7.22 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The company had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.